These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25739815)

  • 21. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
    Sugiyama I; Sadzuka Y
    Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin.
    de Smet M; Hijnen NM; Langereis S; Elevelt A; Heijman E; Dubois L; Lambin P; Grüll H
    Invest Radiol; 2013 Jun; 48(6):395-405. PubMed ID: 23399809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
    Tagami T; Ernsting MJ; Li SD
    J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina.
    Geng S; Yang B; Wang G; Qin G; Wada S; Wang JY
    Nanotechnology; 2014 Jul; 25(27):275103. PubMed ID: 24960297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
    Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
    Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
    Gray BP; McGuire MJ; Brown KC
    PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing tumor penetration and targeting using size-minimized and zwitterionic nanomedicines.
    Zhang Y; Chen W; Yang C; Fan Q; Wu W; Jiang X
    J Control Release; 2016 Sep; 237():115-24. PubMed ID: 27397491
    [No Abstract]   [Full Text] [Related]  

  • 39. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
    van Meerten T; Hagenbeek A
    Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced drug delivery using sonoactivatable liposomes with membrane-embedded porphyrins.
    Wang X; Yan F; Liu X; Wang P; Shao S; Sun Y; Sheng Z; Liu Q; Lovell JF; Zheng H
    J Control Release; 2018 Sep; 286():358-368. PubMed ID: 30075210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.